224 related articles for article (PubMed ID: 36479108)
1. Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer.
Liu C; Xiao H; Cui L; Fang L; Han S; Ruan Y; Zhao W; Zhang Y
Front Immunol; 2022; 13():1039631. PubMed ID: 36479108
[TBL] [Abstract][Full Text] [Related]
2. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
3. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.
Lin Y; Luo S; Luo M; Lu X; Li Q; Xie M; Huang Y; Liao X; Zhang Y; Li Y; Liang R
Mol Carcinog; 2023 Sep; 62(9):1271-1283. PubMed ID: 37232365
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review.
Guven DC; Kavgaci G; Erul E; Syed MP; Magge T; Saeed A; Yalcin S; Sahin IH
Oncologist; 2024 May; 29(5):e580-e600. PubMed ID: 38309719
[TBL] [Abstract][Full Text] [Related]
7. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
[TBL] [Abstract][Full Text] [Related]
8. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer.
Li S; Na R; Li X; Zhang Y; Zheng T
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188758. PubMed ID: 35809762
[TBL] [Abstract][Full Text] [Related]
9. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
12.
Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies.
Han YJ; Shao CY; Yao Y; Zhang Z; Fang MZ; Gong T; Zhang YJ; Li M
Postgrad Med J; 2024 May; 100(1184):373-381. PubMed ID: 38211949
[TBL] [Abstract][Full Text] [Related]
14. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
[TBL] [Abstract][Full Text] [Related]
15. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
16. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
17. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology.
Voutsadakis IA
Cancer Treat Res Commun; 2023; 36():100746. PubMed ID: 37494750
[TBL] [Abstract][Full Text] [Related]
18. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
Yang Y; Meng WJ; Wang ZQ
Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
